IN2014MN00955A - - Google Patents

Info

Publication number
IN2014MN00955A
IN2014MN00955A IN955MUN2014A IN2014MN00955A IN 2014MN00955 A IN2014MN00955 A IN 2014MN00955A IN 955MUN2014 A IN955MUN2014 A IN 955MUN2014A IN 2014MN00955 A IN2014MN00955 A IN 2014MN00955A
Authority
IN
India
Prior art keywords
immunomodulator
therapy
ultrasound
embolisation
cyberknife
Prior art date
Application number
Other languages
English (en)
Inventor
Charles Akle
Satvinder Mudan
John Grange
Original Assignee
Immodulon Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immodulon Therapeutics Ltd filed Critical Immodulon Therapeutics Ltd
Publication of IN2014MN00955A publication Critical patent/IN2014MN00955A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN955MUN2014 2011-12-02 2012-12-03 IN2014MN00955A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1120779.2A GB201120779D0 (en) 2011-12-02 2011-12-02 Cancer therapy
PCT/GB2012/052992 WO2013079980A1 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer

Publications (1)

Publication Number Publication Date
IN2014MN00955A true IN2014MN00955A (ja) 2015-04-24

Family

ID=45509083

Family Applications (1)

Application Number Title Priority Date Filing Date
IN955MUN2014 IN2014MN00955A (ja) 2011-12-02 2012-12-03

Country Status (15)

Country Link
US (4) US20140356397A1 (ja)
EP (1) EP2785361B1 (ja)
JP (1) JP6085611B2 (ja)
KR (1) KR20140097419A (ja)
CN (1) CN104023733A (ja)
AU (1) AU2012343536B2 (ja)
BR (1) BR112014012880A2 (ja)
CA (1) CA2857429A1 (ja)
GB (1) GB201120779D0 (ja)
IL (1) IL232890A0 (ja)
IN (1) IN2014MN00955A (ja)
MX (1) MX2014006511A (ja)
RU (1) RU2014121335A (ja)
SG (1) SG11201402396XA (ja)
WO (1) WO2013079980A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11963716B2 (en) 2010-07-19 2024-04-23 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
EA201691073A1 (ru) * 2013-12-05 2016-12-30 РФЕМБ ХОЛДИНГС, ЭлЭлСи Иммунотерапия рака с помощью радиочастотного электрического пробоя мембраны (rf-emb)
GB201322725D0 (en) * 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
KR102128856B1 (ko) * 2015-01-30 2020-07-02 알에프이엠비 홀딩스, 엘엘씨 고주파 전기적 막 파괴를 이용하여 생명체의 바람직하지 않은 연조직을 절제하는 시스템
CA2990107A1 (en) 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
RU2596505C1 (ru) * 2015-07-02 2016-09-10 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) Способ лечения онкологических больных цитотоксическими лимфоцитами
US10478194B2 (en) * 2015-09-23 2019-11-19 Covidien Lp Occlusive devices
US11612426B2 (en) 2016-01-15 2023-03-28 Immunsys, Inc. Immunologic treatment of cancer
AU2017249500A1 (en) * 2016-04-14 2018-11-01 Feldreich Caro Ruiz AB An apparatus for use in irradiation therapy comprising ionization module and UV-light source
EP3600551A1 (en) 2017-03-28 2020-02-05 Emblation Limited Stenosis treatment
EP3654976A1 (en) 2017-07-21 2020-05-27 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agents
RU2664597C1 (ru) * 2017-12-12 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения больных первично операбельным и местно-распространенным неоперабельным раком молочной железы
CN113164632A (zh) 2018-12-03 2021-07-23 融合制药公司 放射性免疫缀合物与检查点抑制剂组合疗法
AU2020414040A1 (en) * 2019-12-27 2022-08-18 Zeria Pharmaceutical Co., Ltd. Cancer treatment method and medicine
WO2023007107A1 (en) * 2021-07-27 2023-02-02 Immodulon Therapeutics Limited A mycobacterium for use in cancer therapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5207223A (en) 1990-10-19 1993-05-04 Accuray, Inc. Apparatus for and method of performing stereotaxic surgery
DE69126668T2 (de) * 1990-11-08 1997-10-23 Univ London Mycobacterium als adjuvans für antigene
US5458125A (en) 1994-01-28 1995-10-17 Board Of Directors Of The Leland Standford Jr. University Treatment planning method and apparatus for radiosurgery and radiation therapy
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
WO2000064476A2 (en) 1999-04-23 2000-11-02 Qlt Inc. Immuno-adjuvant pdt treatment of metastatic tumors
WO2003049751A1 (en) * 2001-12-10 2003-06-19 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
ATE481985T1 (de) 2002-07-03 2010-10-15 Ono Pharmaceutical Co Immunpotenzierende zusammensetzungen
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
AU2006306521B2 (en) 2005-10-21 2011-12-22 Medical College Of Georgia Research Institute, Inc. The induction of indoleamine 2,3-dioxygenase in dendritic cells by TLR ligands and uses thereof
US20080318252A1 (en) 2007-04-23 2008-12-25 Scott Kachlany Rapid assay to test anti-cancer drugs under physiological conditions
GB0526033D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Method
WO2007112316A2 (en) * 2006-03-24 2007-10-04 Morton Donald L Mycobacterial immunotherapy for cancer treatment
WO2008110491A2 (en) 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
US8367075B2 (en) 2010-07-02 2013-02-05 Indian Institute Of Science Synergistic combination and method thereof
JP2014511396A (ja) * 2011-03-09 2014-05-15 ザ・ジョンズ・ホプキンス・ユニバーシティ 除去的放射線治療に使用される組成物およびその使用方法
CN103796680A (zh) 2011-06-21 2014-05-14 约翰霍普金斯大学 用于增强针对赘生物的基于免疫的治疗的聚焦放射
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
CA2848985A1 (en) 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
US8617520B2 (en) 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy
GB201308325D0 (en) 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
KR102395498B1 (ko) 2014-01-06 2022-05-09 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
CA2990107A1 (en) 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
CN112672758A (zh) 2018-06-25 2021-04-16 英摩杜伦治疗学公司 癌症治疗

Also Published As

Publication number Publication date
AU2012343536B2 (en) 2017-08-24
US11318193B2 (en) 2022-05-03
JP6085611B2 (ja) 2017-02-22
WO2013079980A1 (en) 2013-06-06
EP2785361A1 (en) 2014-10-08
CN104023733A (zh) 2014-09-03
US20230149525A1 (en) 2023-05-18
US20200338181A1 (en) 2020-10-29
US11554166B2 (en) 2023-01-17
SG11201402396XA (en) 2014-10-30
AU2012343536A1 (en) 2014-06-05
BR112014012880A2 (pt) 2017-06-13
EP2785361B1 (en) 2018-11-28
IL232890A0 (en) 2014-07-31
NZ624994A (en) 2016-10-28
RU2014121335A (ru) 2016-01-27
KR20140097419A (ko) 2014-08-06
GB201120779D0 (en) 2012-01-11
JP2014533743A (ja) 2014-12-15
US20140356397A1 (en) 2014-12-04
MX2014006511A (es) 2014-12-05
US20190224294A1 (en) 2019-07-25
CA2857429A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
IN2014MN00955A (ja)
WO2011137449A3 (en) Method and apparatus for treatment of ocular tissue using combined modalities
Mellal et al. Thermal therapy modalities for cancer treatment: A review and future perspectives
WO2015008154A3 (en) Self-administrable method, system, and apparatus for non-invasive neurostimulation therapy of the brain
US20240123253A1 (en) Photodynamic therapy devices, systems and methods
Ross et al. Laser-tissue interactions
Yin et al. Characteristic analysis of light and heat transfer in photothermal therapy using multiple-light-source heating strategy
CN103638606B (zh) 光热和光动力治疗装置
CN203663257U (zh) 光热和光动力治疗装置
WO2013166504A3 (en) Targeted delivery of active agents using thermally stimulated large increase of perfusion by high intensity focused ultrasound
Yanase et al. Hyperthermia enhances the antitumor effect of photodynamic therapy with ALA hexyl ester in a squamous cell carcinoma tumor model
Yoo et al. Non-ablative fractional thulium laser irradiation suppresses early tumor growth
RU2006101260A (ru) Способ фотодинамической терапии онкологических заболеваний
RU2010129236A (ru) Способ лечения местнораспространенных онкологических заболеваний в эксперименте
Lloyd et al. Laser-Tissue Interactions
RU2015131129A (ru) Способ фотодинамической терапии фоновых и предраковых заболеваний шейки матки
Liu et al. Biophotonics in photomedicine
PH12015502086A1 (en) Ablative immunotherapy
Kim et al. Multi-Lens Array (MLA)-Assisted Power-Modulated Photothermal Therapy for Enhanced Cancer Treatment
Karimian et al. Review the effect of hyperthermia using iron and magnetic nanoparticles in cancer treatment in chemical injuries
Soni et al. Spatiotemporal Temperature in a Tumor During Nanorod Assisted Thermal Therapy
Moretti et al. Conventional and unconventional use of lasers in skin disorders
Ioritani Contact Laser Vaporization of Prostate (CVP) using 980 nm High Power Diode Laser and End-Firing TwisterTM Large Fiber
Lee et al. Use of a 595-nm pulsed-dye laser to treat post-procedure ecchymoses
Betz et al. Interstitial PDT Cancer Treatment